These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

523 related articles for article (PubMed ID: 31983645)

  • 1. Autoimmune polyradiculitis due to combination immunotherapy with ipilimumab and nivolumab for the treatment of metastatic melanoma.
    Lasocki A; Smith K
    J Clin Neurosci; 2020 Apr; 74():240-241. PubMed ID: 31983645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autoimmune Bell's Palsy Following Immunotherapy For Metastatic Melanoma: A Report of 2 Cases.
    Zieman D; Frankel AE
    J Immunother; 2019 Oct; 42(8):318-320. PubMed ID: 31318723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy.
    Tan I; Malinzak M; Salama AKS
    J Immunother Cancer; 2018 Jul; 6(1):77. PubMed ID: 30064495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Seronegative autoimmune autonomic ganglionopathy from dual immune checkpoint inhibition in a patient with metastatic melanoma.
    Gao CA; Weber UM; Peixoto AJ; Weiss SA
    J Immunother Cancer; 2019 Oct; 7(1):262. PubMed ID: 31623673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complete ophthalmoplegia in Ipilmumab and Nivolumab combination treatment for metastatic melanoma.
    Alnabulsi R; Hussain A; DeAngelis D
    Orbit; 2018 Oct; 37(5):381-384. PubMed ID: 29381409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination Nivolumab/Ipilimumab Immunotherapy For Melanoma With Subsequent Unexpected Cardiac Arrest: A Case Report and Review of Literature.
    Khoury ZH; Hausner PF; Idzik-Starr CL; Frykenberg MRA; Brooks JK; Dyalram D; Basile JR; Younis RH
    J Immunother; 2019 Oct; 42(8):313-317. PubMed ID: 31206394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fatal myocarditis and rhabdomyositis in a patient with stage IV melanoma treated with combined ipilimumab and nivolumab.
    Saibil SD; Bonilla L; Majeed H; Sotov V; Hogg D; Chappell MA; Cybulsky M; Butler MO
    Curr Oncol; 2019 Jun; 26(3):e418-e421. PubMed ID: 31285688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Meningeal syndrome in a patient treated with a combination of immune checkpoint inhibitors for a metastatic melanoma].
    Bello-Chavolla OY; Cortes-Arroyo JE; Vargas-Vazquez A; Quiroz-Compean F; Leal-Gutierrez G; Barragan-Dessavre M; Martinez-Samano JE
    Rev Neurol; 2018 Oct; 67(7):279-280. PubMed ID: 30232801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab.
    Hantel A; Gabster B; Cheng JX; Golomb H; Gajewski TF
    J Immunother Cancer; 2018 Jul; 6(1):73. PubMed ID: 30012206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurologic Complications: Effects of Ipilimumab and Nivolumab Therapy in Patients With Metastatic Melanoma.
    Latchman J; Guastella A; Tofthagen C
    Clin J Oncol Nurs; 2019 Aug; 23(4):355-358. PubMed ID: 31322610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interstitial granulomatous dermatitis and concurrent immunotherapy associated encephalitis with nivolumab and ipilimumab.
    Starling CT; Messer AA; Kleiman A; McQuade JL; Glitza IC; Torres-Cabala CA; Heberton M
    Dermatol Online J; 2022 Mar; 28(2):. PubMed ID: 35670686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A case of dual-mechanism immune-related anaemia in a patient with metastatic melanoma treated with nivolumab and ipilimumab.
    Olson DJ; Rajagopal P; Tjota MY; Venkataraman G; Luke JJ; Gajewski TF
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32169870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of Poliosis Following Checkpoint Inhibitor Treatment for Cutaneous Melanoma.
    Ediriwickrema LS; Liu CY; Kikkawa DO; Korn BS
    Ophthalmic Plast Reconstr Surg; 2019; 35(5):e121-e122. PubMed ID: 31373986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.
    Long GV; Atkinson V; Lo S; Sandhu S; Guminski AD; Brown MP; Wilmott JS; Edwards J; Gonzalez M; Scolyer RA; Menzies AM; McArthur GA
    Lancet Oncol; 2018 May; 19(5):672-681. PubMed ID: 29602646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gastrointestinal complications in patients treated with ipilimumab and nivolumab combination therapy or monotherapy.
    Irwin DE; Davis B; Bell JA; Galaznik A; Garcia-Ribas I
    J Comp Eff Res; 2019 Jan; 8(2):81-90. PubMed ID: 30547675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bullous pemphigoid induced by ipilimumab in a patient with metastatic malignant melanoma after unsuccessful treatment with nivolumab.
    Kuwatsuka Y; Iwanaga A; Kuwatsuka S; Okubo Y; Murayama N; Ishii N; Hashimoto T; Utani A
    J Dermatol; 2018 Jan; 45(1):e21-e22. PubMed ID: 28944534
    [No Abstract]   [Full Text] [Related]  

  • 17. Widespread subacute cutaneous lupus erythematosus in a patient receiving checkpoint inhibitor immunotherapy with ipilimumab and nivolumab.
    Kosche C; Owen JL; Choi JN
    Dermatol Online J; 2019 Oct; 25(10):. PubMed ID: 31735010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Type 1 diabetes in a melanoma patient treated with ipilimumab after nivolumab.
    Omodaka T; Kiniwa Y; Sato Y; Suwa M; Sato M; Yamaguchi T; Sato A; Miyake T; Okuyama R
    J Dermatol; 2018 Oct; 45(10):e289-e290. PubMed ID: 29667767
    [No Abstract]   [Full Text] [Related]  

  • 19. Predictors of immunotherapy-induced immune-related adverse events.
    Kartolo A; Sattar J; Sahai V; Baetz T; Lakoff JM
    Curr Oncol; 2018 Oct; 25(5):e403-e410. PubMed ID: 30464691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of Combination Immune Checkpoint Inhibitors Compared to Monotherapy; A Systematic Review and Meta-Analysis.
    Abdelhafeez AAM; Shohdy KS; Ibrahim W
    Cancer Invest; 2020 Mar; 38(3):150-157. PubMed ID: 31977260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.